Predictive factors for work-day loss in Behcet's syndrome: A multi-center study
Makaleler > Tam Makale · 2019
Yazarlar: Gonca Mumcu, Meral Yay, Aysun Aksoy, Mehmet Nedim Tas, Berkan Armagan, Alper Sari, Burçin Cansu Bozca, Emre Tekgoz, Duygu Temiz Karadag, Suade Özlem Badak, Duygu Tecer, Cemal Bes, Ali Sahin, Eren Erken, Ayse Cefle, Muhammet Cinar, Sedat Yilmaz, Umit Karacayli, Erkan Alpsoy, Soner Senel, Sule Yasar Bilge, Timucin Kaifoglu, Omer Karadag, Kenan AKSU, Gökhan KESER, Fatma Alibaz-Oner, Nevsun Inanc, Tulin Ergun, Suzan GÜVEN
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2019, cilt 23, ss 240-246
Özet
Objective The aim of this multi-center study was to assess predictive factors for work-day loss as an indirect cost element in Behcet's syndrome (BS). Methods In this cross-sectional, multi-center study, 834 BS patients (F/M: 441/393, age mean: 38.4 +/- 10.9 years) were included. Data were collected by a questionnaire regarding treatment protocols, disease duration, smoking pattern, frequency of medical visits during the previous year and self-reported work-day loss during the previous year. Results Work-day loss was observed in 16.2% of patients (M/F: 103/32). The percentages of being a smoker (81.8%), using immunosuppressive (IS) medications (82%), and having disease duration <5 years (74%) were higher in male patients with work-day loss (P < .05). The majority of males (90.9%) had more than four clinic visits during the previous year. Moreover, the mean work-day loss (30.8 +/- 57.7 days) was higher in patients with vascular involvement (56.1 +/- 85.9) than those without (26.4 +/- 50.6 days) (P = .046). In addition, increased frequency of ocular involvement (25.9%) was also observed in patients with work-day loss compared to others (8.6%) (P = .059). Conclusion Work-day loss was associated with both vascular and ocular involvement. Close associations were observed among male gender, early period of the disease, frequent medical visits, being a smoker and treatment with IS medications in patients with work-day loss.